Edgar Filing: APPLE ROBERT F - Form 4

APPLE ROB	ERT F										
Form 4											
February 24,	2010										
FORM	4								PPROVAL		
	UNITEDS		URITIES A Vashington,			IGE (COMMISSION	OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or				GES IN BENEFICIAL OWNERSHIP OF SECURITIES 5(a) of the Securities Exchange Act of 1934,					January 31, 2005 average rs per 0.5		
obligation may conti <i>See</i> Instru- 1(b).	nue. Section 17(a)) of the Public		ting Com	pany	Act of	f 1935 or Sectio	n			
(Print or Type R	esponses)										
APPLE ROBERT F Symbol							5. Relationship of Reporting Person(s) to Issuer				
ANTAR				RES PHARMA, INC. [AIS]				(Check all applicable)			
	(First) (M RES PHARMA, HILLIPS BLVD, S	(Mont 02/22	e of Earliest Tr h/Day/Year) 2/2010	ansaction			Director X Officer (give below) Executive Y		o Owner er (specify & CFO		
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
EWING, NJ	08618							More than One Re			
(City)	(State) (Z	Zip) T	able I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed o	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye	Code	on(A) or Dis (D) (Instr. 3, 4	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	02/22/2010		A	50,419 (1)	(D) A	(<u>2</u>)	127,767	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: APPLE ROBERT F - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			Amou Unde Secur	le and int of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	′ (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
APPLE ROBERT F C/O ANTARES PHARMA, INC. 250 PHILLIPS BLVD, SUITE 290 EWING, NJ 08618			Executive Vice President & CFO				
Signatures							

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents a grant of 22,727 shares of common stock, par value \$0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan based on achievement of a performance goal previously established. In addition, 27,692 shares of restricted common stock were granted under the Antares Pharma, Inc. 2008 Equity Compensation Plan in lieu of cash as a partial bonus payment and vest 100% on February 22, 2013.
- (2) Not applicable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.